Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- University of California, Berkeley
- Target Recruit Count
- 80
- Registration Number
- NCT05265546
- Locations
- 🇺🇸
University of California, Berkeley, Berkeley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath